S1019 amends South Carolina’s insurance code to expand and clarify required coverage for cancer screening and diagnostic services. The bill defines key terms such as “cost-sharing requirements,” “health insurance policy,” “mammogram,” and “pap smear,” and it updates the existing statute governing mandated coverage for breast and cervical cancer screening. It also adds a new requirement that individual and group health insurance policies in the state cover prostate cancer examinations, screenings, and diagnostic laboratory work in accordance with the most recent published guidelines of the National Comprehensive Cancer Network.
The bill specifically prohibits health plans from imposing deductibles, copayments, coinsurance, or similar out-of-pocket costs for prostate cancer screening and diagnostic lab services, while preserving the ability of plans to offer more generous coverage. It also includes a federal-law carveout for Health Savings Account-qualified high deductible health plans, so the no-cost-sharing rule is adjusted where necessary to avoid conflict with federal tax rules, except for preventive services already protected under federal law. The act would take effect upon gubernatorial approval.
Impact
If enacted, the bill would amend Section 38-71-145 of the South Carolina Code to require broader cancer-screening coverage in individual and group health insurance policies and health maintenance organization plans. It would eliminate cost-sharing for prostate cancer examinations, screenings, and diagnostic laboratory work, and it would continue existing protections for mammograms and pap smears. The bill would affect insurers, HMOs, fraternal benefit societies, and similar entities operating in South Carolina, subject to ERISA preemption and the federal HSA/high-deductible plan exception.
Sentiment
The available context shows no recorded committee debate or votes, so there is no documented opposition or support in the provided materials. Based on the bill’s subject matter and caption, the measure appears to be framed as a consumer and preventive-health coverage expansion, with an emphasis on reducing financial barriers to prostate cancer screening. The absence of recorded votes or transcripts means the overall sentiment cannot be measured from legislative history in the provided record.
Contention
The main potential point of contention is the mandate that insurers eliminate cost-sharing for prostate cancer screening and related diagnostic lab work, which could raise concerns from insurers about premium impacts and benefit design. Another technical issue is the interaction with federal law, especially for Health Savings Account-qualified high deductible health plans, which the bill addresses through an explicit exception. No specific legislators, committees, or stakeholder groups are identified in the provided materials as having raised objections or support.